Fine Vine: Old Dog,...
Health Care: Drugs
Osiris Therapeutics Inc. (OSIR: NASDAQ)
$11.27 0.67 | 6.32%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 11.27 |
| 52 Week High | 14.46 |
| 52 Week Low | 5.51 |
| Avg. Daily Vol. (Mil) | 0.14 |
| Beta (3 year) | 1.81 |
| Share Related Items | |
| Mkt Cap (Mil) | 371.14 |
| Shares Out (Mil) | 32.93 |
| Float (Mil) | 14.36 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.90 |
| Current Ratio | 7.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 32.38 |
| Price/Book | 10.97 |
| Price/Cash Flow | -28.40 |
| Per Share Data | |
| Earnings | -0.38 |
| Sales | 0.35 |
| Book Value | 1.03 |
| Cash Flow | -0.40 |
| Business Summary | |
|---|---|
| Osiris Therapeutics, Inc. is a stem cell therapeutic company, which is focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. | |
| General Information | |
| 7015 Albert Einstein Drive
Columbia, MD 21046 |
|
| www.osiristx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 59 | |
| CEO: Dr. C. Randal Mills,PhD | |
| Short Interest | |
| Current Month (Mil) | 2.85 |
| Previous Month (Mil) | 3.00 |
| Short Interest Ratio (Days) | 22.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -35.10 |
| Return on Investments | -40.00 |
| Profitability | |
| Gross Margin | 77.50 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with OSIR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- User2012
- ContributorStocks Rising On Unusual Vo...
- UserPharma
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Moving Hig...
- UserE*Trade
- Contributor200 day moving average stocks
Latest OSIR Headlines from TheStreet
- Osiris Therapeutics Inc. Stock Upgraded (OSIR) 03.28.13 | 05:03 am
- 4 Stocks Spiking on Unusual Volume 03.11.13 | 02:03 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Osiris Therapeutics Inc. Stock Downgraded (OSIR) 03.08.13 | 04:03 am
- 10 Biotech Stocks With A History Of Beating Earning Expectations 01.10.13 | 07:01 pm
- 5 Under-$10 Stocks Due to Surge 12.27.12 | 01:12 pm
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris 10.05.12 | 06:10 am
- Biotech Stock Mailbag: Mela, Osiris, Talon 08.03.12 | 06:08 am
Press Releases for OSIR
- Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference - Business Wire 03.14.13 | 07:03 am
- Osiris Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.06.13 | 08:03 am
- Osiris Therapeutics Establishes Direct Sales Force For Grafix® - Business Wire 03.01.13 | 07:03 am
- Osiris Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.22.13 | 05:02 pm
- Osiris Therapeutics Receives Title Of European Orphan Drug Designation For Prochymal® - Business Wire 02.19.13 | 07:02 am
- Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge - Business Wire 02.18.13 | 07:02 pm
- Osiris Therapeutics To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 04:11 pm
- Osiris Therapeutics Reports Third Quarter 2012 Financial Results - Business Wire 11.05.12 | 08:11 am
- Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call - Business Wire 10.29.12 | 04:10 pm
- Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer - Business Wire 10.22.12 | 04:10 pm
Partner Headlines for OSIR
- Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself - Seeking Alpha 03.19.13 | 09:03 am
- Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? - Seeking Alpha 02.27.13 | 09:02 am
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- Neutral on Osiris - Analyst Blog - NASDAQ 09.10.12 | 09:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- These Are Four of the Hottest Biotechs in the Market Right Now - Benzinga 07.05.12 | 01:07 pm
- Healthcare Biz Review: Osiris ACCUSED, Chelsea's BAD NEWS - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Osiris' Prochymal Encourages - Analyst Blog - Zacks 07.03.12 | 05:07 pm
- 6 Profitable Small Cap Healthcare Stocks Holding Large Cash Reserves - Seeking Alpha 06.22.12 | 07:06 pm
